drugset / Trial / NCT05785325
RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
A phase II clinical study of RC48-ADC combined with Bevacizumab as late-line treatment in patients with HER2-expressed metastatic colorectal cancer. A total of 30 patients are planned to be enrolled.
Timeline
- Start
- 2023-08-20
- Primary completion
- 2023-12-01
- Completion
- 2024-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |
| Subject | Disitamab Vedotin | Monoclonal antibody | — | Intravenous |